Cortisol—cause and cure for metabolic syndrome?
Author:
- 17 November 2006
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 23 (12) , 1281-1288
Abstract
Similarities between the metabolic syndrome and Cushing's syndrome, and reversibility of the features of Cushing's syndrome, suggest that cortisol may contribute to the pathophysiology of both conditions and that reducing cortisol action may provide a novel therapeutic approach in the metabolic syndrome. There is substantial evidence that circulating cortisol concentrations are higher in people with hypertension and glucose intolerance. The basis for this activation of the hypothalamic–pituitary–adrenal axis remains uncertain, but it may be attributable to ‘programming’ effects of events in early life, since it is associated with low birth weight. In obese people, intracellular cortisol levels within adipose tissue are further amplified by increased local regeneration of cortisol by the enzyme 11β‐HSD type 1. In mice, transgenic manipulations of 11β‐HSD1 have potent effects on obesity and associated features of the metabolic syndrome. Promising preclinical data suggest that novel 11β‐HSD1 inhibitors will have a role in lowering intracellular cortisol levels as a treatment for the metabolic syndrome. In addition to their metabolic effects, glucocorticoids act in the blood vessel wall. Pharmacoepidemiological studies suggest that glucocorticoid excess is an independent risk factor for cardiovascular disease. Recent data suggest that 11β‐HSD1 within the blood vessel wall influences vascular remodelling and angiogenesis, for example in the myocardium following coronary artery occlusion. Thus, glucocorticoid signalling provides a potentially tractable system to influence both risk factors for, and the outcome of, Type 2 diabetes and cardiovascular disease.Keywords
This publication has 62 references indexed in Scilit:
- Interaction Between an 11βHSD1 Gene Variant and Birth Era Modifies the Risk of Hypertension in Pima IndiansHypertension, 2004
- Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic SyndromeCirculation, 2002
- Expression of the mRNA Coding for 11 -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization StudyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Skeletal Muscle Glucocorticoid Receptor Density and Insulin ResistanceJAMA, 2002
- Distinguishing the Activities of 11 -Hydroxysteroid Dehydrogenases in Vivo Using Isotopically Labeled CortisolThe Journal of Clinical Endocrinology & Metabolism, 2002
- Altered Control of Cortisol Secretion in Adult Men with Low Birth Weight and Cardiovascular Risk FactorsThe Journal of Clinical Endocrinology & Metabolism, 2001
- The role of corticosteroids in the regulation of vascular toneCardiovascular Research, 1999
- Elevated Plasma Cortisol Concentrations: A Link between Low Birth Weight and the Insulin Resistance Syndrome?The Journal of Clinical Endocrinology & Metabolism, 1998
- Increased Vasoconstrictor Sensitivity to Glucocorticoids in Essential HypertensionHypertension, 1996
- Deficient inactivation of cortisol by 11β‐hydroxysteroid dehydrogenase in essential hypertensionClinical Endocrinology, 1993